ChromaDex shares are trading higher after the company received exclusive FDA Orphan Drug Designation and Rare Pediatric Disease Designation for Nicotinamide Riboside Chloride in the treatment of Ataxia Telangiectasia.
Portfolio Pulse from Benzinga Newsdesk
ChromaDex shares are trading higher after the company received exclusive FDA Orphan Drug Designation and Rare Pediatric Disease Designation for Nicotinamide Riboside Chloride in the treatment of Ataxia Telangiectasia.
June 07, 2024 | 12:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ChromaDex shares are trading higher after receiving FDA Orphan Drug Designation and Rare Pediatric Disease Designation for Nicotinamide Riboside Chloride in treating Ataxia Telangiectasia.
The FDA designations are significant milestones that can lead to market exclusivity and potential financial incentives, driving investor optimism and pushing the stock price higher.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100